Ondansetron Dosing Recommendations for Chemotherapy-Induced Nausea and Vomiting

Dosing by Emetogenic Risk

• The American Society of Clinical Oncology recommends administering ondansetron 24 mg orally as a single dose 30 minutes before highly emetogenic chemotherapy, in combination with dexamethasone and an NK1 receptor antagonist, with a complete response rate of 66% 1, 2
• For moderately emetogenic chemotherapy, the National Comprehensive Cancer Network suggests administering ondansetron 8 mg orally or IV 30 minutes before chemotherapy, then 8 mg eight hours later, followed by 8 mg twice daily for 2 days after chemotherapy completion, with a complete response rate of 61% 1, 2
• The European Society for Medical Oncology recommends continuing ondansetron for 2-3 days after highly emetogenic chemotherapy completion 1

Route of Administration

• The American Society of Health-System Pharmacists prefers oral dosing for routine prophylaxis, with a Level of Evidence I and Grade A recommendation 3, 2
• The Society of Clinical Oncology advises switching to IV administration if the patient has active nausea and vomiting 3, 2

Radiation-Induced Nausea and Vomiting

• The National Cancer Institute recommends administering ondansetron 8 mg orally or IV before each radiation fraction, continued daily on radiation days plus 1-2 days after completion, for high-risk radiation 1

Breakthrough/Rescue Dosing

• The American Society of Clinical Oncology suggests administering 16 mg orally or IV as a single PRN dose if nausea persists despite scheduled ondansetron, with a maximum dose of 24 mg in 24 hours 1

Critical Prescribing Pitfalls

• The FDA warns against using ondansetron 8 mg twice daily or 32 mg once daily for highly emetogenic chemotherapy due to insufficient efficacy 1
• The FDA also warns against using ondansetron 8 mg three times daily for moderately emetogenic chemotherapy, as this is not a recommended regimen 1
• The FDA recommends a maximum single IV dose of 16 mg due to cardiac safety concerns, such as QT prolongation risk 1
• The European Society for Medical Oncology advises reducing corticosteroid dose by 50% when combining ondansetron with aprepitant due to CYP3A4 interactions 1